1.
Rev. Assoc. Med. Bras. (1992, Impr.)
;
67(supl.1): 18-21, 2021.
Article
Dans Anglais
| LILACS
| ID: biblio-1287838
Résumé
SUMMARY COVID-19 infection is more severe in patients with type 2 diabetes mellitus (DM2). The severity of this viral infection is associated with an intense inflammatory activity. DM2 is a disease that also determines a greater degree of systemic inflammation. This is due to hyperglycemia, the higher prevalence of sleep disorders and also the low levels of melatonin, a substance with anti-inflammatory actions, in these patients. In this article, we suggest that exogenous melatonin may have an important anti-inflammatory role in preventing severe forms of COVID -19 in patients with DM2.
Sujets)
Diabète de type 2/complications , Diabète de type 2/traitement médicamenteux , COVID-19 , Hyperglycémie , SARS-CoV-2 , Mélatonine/usage thérapeutique
2.
Rev. Assoc. Med. Bras. (1992, Impr.)
;
67(supl.1): 8-9, 2021.
Article
Dans Anglais
| LILACS
| ID: biblio-1287860